Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension

Clinical and Experimental Hypertension : CHE
Yoshitaka HirookaKenji Sunagawa

Abstract

Endothelial function is impaired in hypertensive patients. Decreased nitric oxide production and increased oxidative stress are involved in this abnormality. The aim of the present study was to evaluate whether endothelial function and oxidative stress differ following long-term antihypertensive treatment with an angiotensin type 1 receptor blocker, valsartan, or a calcium channel blocker, amlodipine, in patients with essential hypertension. Hypertensive patients were treated with valsartan (80-160 mg/day) or amlodipine (5-10 mg/day) for one year (n = 9 for each). The baseline blood pressure was similar between groups, and the magnitude of the decreases in blood pressure did not differ during treatment at three months, six months, or one year. Endothelial function and oxidative stress markers were examined before and after treatment. Endothelial function, assessed by flow-mediated vasodilation, was significantly improved in hypertensive patients treated with valsartan (5.8 +/- 1.2 to 10.7 +/- 1.4 %, p < 0.01) but not in those treated with amlodipine. The percent increase in vasodilation induced by sublingual nitroglycerin did not differ between the two groups. As markers of oxidative stress, urinary excretion of 8-isoprostane a...Continue Reading

References

Jan 15, 2002·Journal of the American College of Cardiology·Mary C CorrettiUNKNOWN International Brachial Artery Reactivity Task Force
Jul 24, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Young-Keun OnYoung-Bae Park
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Apr 30, 2003·Hypertension·Lorenzo GhiadoniAntonio Salvetti
Sep 6, 2003·Journal of the American College of Cardiology·Kwang Kon KohEak Kyun Shin
Sep 12, 2003·Trends in Pharmacological Sciences·Hua CaiDavid G Harrison
Jan 14, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yoshitaka HirookaAkira Takeshita
Aug 11, 2004·The Journal of Pharmacology and Experimental Therapeutics·Luigi SironiElena Tremoli
Oct 20, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Atsushi HozawaIchiro Tsuji
Jan 12, 2005·Journal of Hypertension·John DeanfieldUNKNOWN Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension
Jan 22, 2005·Journal of Hypertension·Hanspeter BrunnerUNKNOWN Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension
Mar 25, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tetsuya OshimaMasayuki Kambe
May 24, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yoshitaka HirookaKenji Sunagawa

❮ Previous
Next ❯

Citations

Jan 26, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Min ZhuoLi Zuo
Feb 20, 2009·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Enrique Sánchez-LemusJuan M Saavedra
Sep 23, 2010·Vascular Health and Risk Management·De-Zai Dai, Yin Dai
Oct 20, 2009·Current Medical Research and Opinion·Francesco LocatelliTevfik Ecder
Nov 15, 2012·Clinical and Experimental Hypertension : CHE·Murat UnluKenan Sağlam
Jan 29, 2011·Clinical and Experimental Hypertension : CHE·Tetsuro ShishidoIsao Kubota
Apr 11, 2012·International Journal of Vascular Medicine·Michiaki MiyamotoNobuyuki Taniguchi
Jan 8, 2013·Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi·Takashi Hitsumoto
Jul 17, 2009·Cardiovascular Therapeutics·Nikolaos TzemosThomas M MacDonald
Mar 15, 2016·Canadian Journal of Physiology and Pharmacology·Hussein F SakrAyman Z Elsamanoudy
Feb 9, 2010·International Journal of Cardiology·Mukesh SinghSandeep Khosla
Aug 14, 2012·Journal of cardiology·Takashi Hitsumoto
Dec 10, 2016·The Indian Journal of Medical Research·Miroslav RadenkovicMilica Prostran
May 12, 2017·The Korean Journal of Internal Medicine·Jun Sung Moon, Kyu Chang Won
Feb 5, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Annabella Braschi
Oct 24, 2009·Current Opinion in Lipidology·Marietta CharakidaJohn E Deanfield
Feb 25, 2009·Expert Opinion on Pharmacotherapy·Silvia BarraGiovanni Gaeta
Jul 13, 2013·Wiener klinische Wochenschrift·Hana Matejovska KubesovaJan Matejovsky
Jun 14, 2017·Oxidative Medicine and Cellular Longevity·Francesco AngeliniElena De Falco
Nov 30, 2018·JAMA Cardiology·Kelsie E OatmenFrancis G Spinale
Mar 26, 2021·Oxidative Medicine and Cellular Longevity·Kacper Maksymilian MilMateusz Maciejczyk
Oct 17, 2020·Future Cardiology·Sarah J Wang, Gary E Sander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.